Investor Centre

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various forms of Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical to intercede in disease processes. Alterity is located in Melbourne, Australia and San Francisco, California, USA. The Company is listed on the Australian Securities Exchange (ASX: ATH) and NASDAQ (NASDAQ: ATHE).

Investment Highlights

Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
ATH434 has completed its Phase 1 clinical trial program.
First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
FDA Orphan Drug designation in the U.S. and EU for ATH434 for the treatment of MSA received.
Significant market potential in MSA – estimated peak sales of US$725M.

Investor Resources

Corporate presentations

May 26, 2023

Corporate Presentation May 2023

4 MB

Analyst Reports

August 13, 2020

July 2020 – MST Access – ATH Initiation Report

pdf

1 MB

ASX Announcements

2022

May 26, 2022	Alterity to Participate in the Benchmark Company Conference – 26 May 2022	156 KB
May 4, 2022	Change in substantial holding – 4 May 2022	829 KB
April 27, 2022	UK Regulatory Authorisation to Proceed with Phase 2 Trial – 27 April 2022	226 KB
April 7, 2022	Presentation of bioMUSE Data at the AAN Annual Meeting – 7 April 2022	255 KB
March 22, 2022	Change in substantial holding – 22 March 2022	3 MB
March 17, 2022	Change in substantial holding – 17 March 2022	828 KB
March 15, 2022	Alterity to participate in Sachs Neuroscience Conference – 15 March 2022	157 KB
March 7, 2022	ATH – Investor Presentation – 7 March 2022	5 MB
March 7, 2022	Alterity to present at 34th Annual Roth Conference – 7 March 2022	157 KB
March 1, 2022	NASDAQ Non-Compliance Notice Received – 28 February 2022	219 KB
March 1, 2022	Half-Year Report Ending 31 December 2021	388 KB
January 28, 2022	New publication shows ATH434 rescues neurons in MSA model – 28 January 2022	271 KB
January 27, 2022	Appendix 4C – Q2 FY22 Quarterly Cash Flow Report – 27 January 2022	422 KB
January 24, 2022	Change in substantial holding – 20 January 2022	853 KB
January 24, 2022	Response to ASX Query – 12 January 2022	218 KB
January 24, 2022	New US Patent for Compounds to Treat Neurodegeneration- 06 January 2022	273 KB
January 24, 2022	Change in substantial holding -05 January 2022	1 MB
January 24, 2022	Alterity to present at H.C. Wainwright Conference – 05 January 2022	197 KB
January 24, 2022	Final Directors Interest Notice x 2 – 05 January 2022	283 KB
January 24, 2022	Notification of cessation of securities – 05 January 2022	22 KB
January 24, 2022	Alterity announces resignation of Non-Executive Directors – 04 January 2022	183 KB

2021

January 24, 2022	Change in substantial holding – 20 December 2021		892 KB
January 24, 2022	Notification of cessation of securities – 15 December 2021		22 KB
January 24, 2022	First Regulatory Authorization to Proceed with Phase 2 Trial – 14 December 2021		252 KB
January 24, 2022	Notification regarding unquoted securities – 09 December 2021		36 KB
January 24, 2022	Change in substantial holding – 02 December 2021		829 KB
January 24, 2022	Change in substantial holding – 22 November 2021		826 KB
January 24, 2022	Alterity to present at upcoming investor conferences – 22 November 2021		157 KB
January 24, 2022	Results of Annual General Meeting – 12 November 2021		180 KB
January 24, 2022	ATH Annual General Meeting Presentation – 12 November 2021		3 MB
January 24, 2022	Chairmans Address 2021 Annual General Meeting -12 November 2021		201 KB
January 24, 2022	Alterity presents at American Autonomic Society Meeting – 09 November 2021		273 KB
January 24, 2022	New Data Advance ATH434 as Neurodegeneration treatment – 04 November 2021		262 KB
November 3, 2021	Notice of change of interests of substantial holder – 3 November 2021		827 KB
October 19, 2021	Expanded ATH434 Phase 2 Clinical Development Program – 19 October 2021	pdf	276 KB
October 11, 2021	Notice of Annual General Meeting _Proxy Form – 11 October 2021	pdf	745 KB
September 20, 2021	Presentation of New Biomarker Data at Scientific Congress – 20 Sept 2021	pdf	260 KB
September 3, 2021	Alterity Therapeutics filed Form 20-F and XBRL data with SEC – 3 Sept. 2021	pdf	202 KB
September 1, 2021	Notice of change of interests of substantial holder – 1 Sept 2021	pdf	586 KB
September 1, 2021	Appendix 4E and Annual Report 2021 – 1 Sept 2021	pdf	3 MB
September 1, 2021	Appendix 4G and Corporate Governance Statement 2021 – 1 Sept 2021	pdf	345 KB
August 12, 2021	Notice of change of interests of substantial holder – 12 August 2021	pdf	828 KB
August 4, 2021	New US Patent Expands Neurodegeneration Treatment Portfolio – 4 August 2021	pdf	250 KB
July 30, 2021	Appendix 4C- Q4 FY21 Quarterly Cash Flow Report – 30 July 2021	pdf	411 KB
July 15, 2021	New Publication Demonstrates ATH434 is Neuroprotective – 15 July 2021	pdf	340 KB
July 13, 2021	Notice of change of interests of substantial holder -13 July 2021	pdf	816 KB
July 9, 2021	Notice of change of interests of substantial holder – 9 July 2021	pdf	933 KB
July 9, 2021	Notice of change of interests of substantial holder – 9 July 2021	pdf	819 KB
July 8, 2021	Notice of change of interests of substantial holder – 8 July 2021	pdf	521 KB
July 6, 2021	Notice of change of interests of substantial holder – 6 July 2021	pdf	521 KB
July 5, 2021	Application for quotation of securities – 5 July 2021	pdf	31 KB
July 2, 2021	Proposed issue of securities – 2 July 2021	pdf	29 KB
July 1, 2021	New US patent targeting major neurodegenerative diseases – 1 July 2021	pdf	237 KB
June 30, 2021	Notice of change of interests of substantial holder – 30 June 2021	pdf	825 KB
June 23, 2021	EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial – 23 June 2021	pdf	212 KB
June 17, 2021	MST Access Micro and Small Caps Conference Presentation – June 2021	pdf	2 MB
June 16, 2021	Alterity to Present at MST Access Australian Micro & Small Caps Conference – 16 June 2021	pdf	203 KB
April 29, 2021	Appendix 4C and Q3 FY 21 Quarterly Cash Flow Report – 29 April 2021	pdf	418 KB
April 28, 2021	Notice of change of interests of substantial holder – 28 April 2021	pdf	587 KB
April 26, 2021	Notice of ceasing to be a substantial holder – 23 April 2021	pdf	81 KB
April 21, 2021	ATH434 protects brain cells and improves motor function – 21 April 2021	pdf	216 KB
April 20, 2021	Appendix 3G – 20 April 2021	pdf	344 KB
March 16, 2021	Notice of change of interests of substantial holder – 15 March 2021	pdf	85 KB
March 10, 2021	Alterity presents to US investors at HC Wainwright Global Life Science Conference – 10 March 2021	pdf	2 MB
February 26, 2021	Notice of change of interests of substantial holder – 26 February 2021	pdf	85 KB
February 26, 2021	Alterity to present at 7th International Congress of MSA – 26 February 2021	pdf	200 KB
February 25, 2021	Half-Year Financial Report – 25 February 2021	pdf	374 KB
February 22, 2021	Notice of change of interests of substantial holder – 22 February 2021	pdf	586 KB
February 16, 2021	Notice of change of interests of substantial holder – 16 February 2021	pdf	816 KB
February 15, 2021	Notice of change of interests of substantial holder – 15 February 2021	pdf	83 KB
February 15, 2021	Notice of change of interests of substantial holder (BNYMC) – 15 February 2021	pdf	585 KB
February 12, 2021	Notice of change of interests of substantial holder – 12 February 2021	pdf	83 KB
February 11, 2021	Appendix 2A and Section 708A Cleansing Notice – 11 February 2021	pdf	377 KB
February 11, 2021	Notice of change of interests of substantial holder – 11 February 2021	pdf	823 KB
February 11, 2021	Proposed Issue of Securities – ATH – 10 February 2021	pdf	28 KB
February 9, 2021	Michael J Fox grant for Parkinson’s research on ATH434 – 9 February 2021	pdf	193 KB
January 29, 2021	Appendix 4C- Q2 FY21 Quarterly Cash Flow Report – 28 January 2021	pdf	339 KB
January 15, 2021	Notice of change of interests of substantial holder – 14 January 2021	pdf	84 KB
January 11, 2021	Alterity participates in world’s largest virtual healthcare conference JP Morgan – 11 January 2021	pdf	201 KB
January 7, 2021	Dr David Stamler Appointed CEO – 7 January 2021	pdf	253 KB

2020

December 31, 2020	Notice of change of interests of substantial holder – 29 December 2020	pdf	820 KB
December 24, 2020	Form F-3 – 24 December 2020	pdf	300 KB
December 21, 2020	New commercial opportunity for PBT2 – 21 December 2020	pdf	283 KB
December 18, 2020	Notice of change of interests of substantial holder – 18 December 2020	pdf	586 KB
December 17, 2020	Form 6-K – 17 December 2020	pdf	237 KB
December 17, 2020	Prospectus Supplement – 17 December 2020	pdf	664 KB
December 10, 2020	Notice of change of interests of substantial holder – 10 December 2020	pdf	820 KB
December 7, 2020	Notice of change of interests of substantial holder – 4 December 2020	pdf	814 KB
December 3, 2020	Form S-8 – 3 December 2020	pdf	171 KB
December 2, 2020	Alterity presents at Finance News Network – 2 December 2020	pdf	653 KB
December 1, 2020	Notice of change of interests of substantial holder (Life Bio) – 1 December 2020	pdf	965 KB
December 1, 2020	Notice of change of interests of substantial holder – 1 December 2020	pdf	586 KB
November 29, 2020	Notice of change of interests of substantial holder (BNYMC) – 25 November 2020	pdf	585 KB
November 29, 2020	Notice of change of interests of substantial holder – 26 November 2020	pdf	152 KB
November 29, 2020	Notice of initial substantial holder – 26 November 2020	pdf	84 KB
November 25, 2020	Notice of change of interests of substantial holder – 25 November 2020	pdf	585 KB
November 24, 2020	Prospectus filed pursuant to SEC Rule 424(b)(3) – 24 November 2020	pdf	261 KB
November 24, 2020	Appendix 3G – 24 November 2020	pdf	345 KB
November 24, 2020	Appendix 2A – 24 November 2020	pdf	377 KB
November 24, 2020	Notice of change of interests of substantial holder – 24 November 2020	pdf	152 KB
November 23, 2020	Notice of change of interests of substantial holder – 23 November 2020	pdf	653 KB
November 19, 2020	Notice of change of interests of substantial holder – 18 November 2020	pdf	587 KB
November 18, 2020	Alterity Therapeutics Constitution (Amended) – 18 November 2020	pdf	433 KB
November 18, 2020	Results of 2020 AGM – 18 November 2020	pdf	191 KB
November 18, 2020	Chairman’s Address to Shareholders 2020 AGM – 18 November 2020	pdf	211 KB
November 18, 2020	AGM 2020 Presentation – 18 November 2020	pdf	2 MB
November 17, 2020	Ceasing to be a substantial holder – 16 November 2020	pdf	453 KB
November 16, 2020	Form F-3 – 16 November 2020	pdf	476 KB
November 16, 2020	Notice of ceasing to be a substantial holder – 16 November 2020	pdf	236 KB
November 16, 2020	US patent for next generation neurodegenerative diseases – 16 November 2020	pdf	181 KB
November 13, 2020	Notice of initial substantial holder – 13 November 2020	pdf	428 KB
October 30, 2020	Appendix 4C- Q1 FY21 Quarterly Cash Flow Report – 30 October 2020	pdf	354 KB
October 27, 2020	Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study – 27 October 2020	pdf	184 KB
October 27, 2020	Notice of change of interests of substantial holder – 27 October 2020	pdf	588 KB
October 26, 2020	Notice of change of interests of substantial holder – 26 October 2020	pdf	2 MB
October 23, 2020	Alterity completes Placement Tranche 1 raising $10M – 23 October 2020	pdf	206 KB
October 23, 2020	Appendix 2A and Section 708A Cleansing Notice – 23 October 2020	pdf	369 KB
October 20, 2020	Notice of Annual General Meeting 2020	pdf	706 KB
October 16, 2020	Proposed issue of securities – ATH – 16 October 2020	pdf	32 KB
October 16, 2020	Proposed issue of securities – ATH – 16 October 2020	pdf	29 KB
October 16, 2020	Alterity raises $35M in placement to institutional investors – 16 October 2020	pdf	235 KB
October 12, 2020	Trading Halt – 12 October 2020	pdf	165 KB
October 6, 2020	Form F-3 – 6 October 2020	pdf	295 KB
September 24, 2020	Form S-8 – 24 September 2020	pdf	126 KB
September 22, 2020	Change of Directors Interest Notice x5 – 21 September 2020	pdf	341 KB
September 21, 2020	Appendix 3G – 18 September 2020	pdf	352 KB
September 16, 2020	Form 20-F 2020	pdf	2 MB
September 16, 2020	Alterity filed Form 20-F and XBRL data with SEC September 2020	pdf	176 KB
September 16, 2020	Annual Report 2020	pdf	2 MB
September 9, 2020	Update on 2020 Annual Report – 9 September 2020	pdf	178 KB
September 9, 2020	Appendix 4G and 2020 Corporate Governance Statement – 9 September 2020	pdf	374 KB
September 4, 2020	Results of General Meeting – 3 September 2020	pdf	170 KB
August 31, 2020	Appendix 4E Year ended 30 June 2020	pdf	454 KB
August 17, 2020	Notice of change of interests of substantial holder – 17 August 2020	pdf	586 KB
August 3, 2020	Notice of General Meeting and Explanatory Memorandum – August 2020	pdf	591 KB
July 15, 2020	Notice of change of interests of substantial holder – 15 July 2020	pdf	124 KB
July 13, 2020	Notice of change of interests of substantial holder – 13 July 2020	pdf	621 KB
July 9, 2020	Notice of change of interests of substantial holder – 9 July 2020	pdf	620 KB
July 8, 2020	Notice of change of interests of substantial holder – 8 July 2020	pdf	620 KB
July 7, 2020	Notice of change of interests of substantial holder – 7 July 2020	pdf	1,014 KB
July 6, 2020	Notice of change of interests of substantial holder – 6 July 2020	pdf	125 KB
July 2, 2020	Appendix 2A and Section 708A(5) Cleansing Notice- July 2020	pdf	379 KB
July 1, 2020	Proposed Issue of Securities – July 2020	pdf	28 KB
July 1, 2020	Response to ASX Price Query – July 2020	pdf	1,003 KB
June 9, 2020	Notice of change of interests of substantial holder – 9 June 2020	pdf	127 KB
May 28, 2020	Notice of change of interests of substantial holder – 28 May 2020	pdf	140 KB
May 27, 2020	Notice of change of interests of substantial holder – 27 May 2020	pdf	123 KB
May 26, 2020	Appendix 2A and Section 708A(5) Cleansing Notice- May 2020	pdf	353 KB
May 25, 2020	Proposed Issue of Securities – May 2020	pdf	29 KB
May 21, 2020	Alterity Presents Data on ATH434 to the American Academy of Neurology – May 2020	pdf	204 KB
April 22, 2020	NASDAQ Temporary Relief – April 2020	pdf	194 KB
March 27, 2020	Appendix 2A – March 2020	pdf	383 KB
March 26, 2020	Proposed Issue of Securities – March 2020	pdf	28 KB
February 7, 2020	Non-Compliance Notice Regarding Minimum Bid Requirement	pdf	214 KB
January 21, 2020	Appendix 3B – January 2020	pdf	343 KB

2019

December 11, 2019	Upcoming release of warrants from voluntary escrow December 2019	pdf	149 KB
November 26, 2019	Results of AGM 2019	pdf	169 KB
November 26, 2019	Chairman’s Address 2019 AGM	pdf	156 KB
November 22, 2019	Appendix 3B – November 2019	pdf	344 KB
October 25, 2019	Notice of AGM 2019	pdf	1 MB
September 2, 2019	Alterity filed Form 20-F and XBRL data with the SEC 2019	pdf	158 KB
August 20, 2019	Notice of Change of Interests of Substantial Holder August 2019	pdf	1,006 KB
August 5, 2019	Upcoming Release of Shares from Voluntary Escrow – August 2019	pdf	266 KB
August 1, 2019	Appendix 3B – New Issue Announcement – August 2019	pdf	350 KB
August 1, 2019	Quarterly Cash Flow Report – June 2019	pdf	373 KB
July 29, 2019	Successful Completion of Phase 1 Clinical Trial – July 2019	pdf	201 KB
June 12, 2019	Alterity presents at the American Academy of Neurology	pdf	238 KB
June 12, 2019	Alterity commences US investor meetings 2019	pdf	205 KB
June 12, 2019	Becoming a substantial shareholder 2019	pdf	2 MB
June 12, 2019	Form 603 Notice lodged by Bank of New York Mellon	pdf	205 KB
June 12, 2019	Alterity Thereapeutics commences US investor meetings2019	pdf	205 KB
June 4, 2019	Notice of Ceasing to be a Substantial Holder ATH – June 2019	pdf	90 KB
June 4, 2019	Alterity Therapeutics Investor Presentation to Finance News Network Conference – Jun 2019	pdf	1 MB
May 23, 2019	Prospectus filed pursuant to SEC Rule 424(b)(3) – May 2019	pdf	433 KB
May 20, 2019	Upcoming Release of Shares from Escrow – May 2019	pdf	203 KB
May 14, 2019	Form F-3 – May 2019	pdf	857 KB
April 10, 2019	Becoming A Substantial Shareholder Alterity – Apr 2019	pdf	723 KB
April 10, 2019	Appendix 3X – Initial Directors Interest Notice DS – Apr 2019	pdf	125 KB
April 10, 2019	Appendix 3X – Initial Directors Interest Notice TE – Apr 2019	pdf	126 KB
April 10, 2019	Appendix 3Z – Final Directors Interest Notice IS – Apr 2019	pdf	127 KB
April 10, 2019	Appendix 3Z – Final Directors Interest Notice GM – Apr 2019	pdf	127 KB
April 10, 2019	Notice of Initial Substantial Holder Life Biosciences – Apr 2019	pdf	1 MB
March 21, 2019	Appendix 3B – Mar 2019	pdf	318 KB
March 6, 2019	Notice of General Meeting – Apr 2019	pdf	3 MB
March 5, 2019	Notice of General Meeting and Explanatory Memorandum – Mar 2019	pdf	3 MB
January 9, 2019	Notice of ceasing to be a substantial holder MUFG – Jan 2019	pdf	165 KB
January 9, 2019	Notice of Ceasing to be a Substantial Holder MS – Jan 2019	pdf	263 KB
January 7, 2019	Prana Biotechnology BSC Presentation – Jan 2019	pdf	1 MB

2018

February 10, 2019	Appendix 3B – Cleansing Notice – Feb 2018	pdf	362 KB
January 7, 2019	Form 603 – Notice of Initial Substantial Holder Morgan Stanley – Jan 2018	pdf	543 KB
January 7, 2019	Form 603 – Notice of Initial Substantial Holder MUFG – Jan 2018	pdf	457 KB
January 7, 2019	Appendix 3B – Jan 2018	pdf	955 KB
December 23, 2018	PBT Trading Halt – Dec 2018	pdf	459 KB
December 4, 2018	Form S-8 Dec 2018	pdf	271 KB
November 19, 2018	Appendix 3B – Nov 2018	pdf	940 KB
November 19, 2018	Appendix 3Y Change of Director’s Interest Notice – Nov 2018	pdf	456 KB
November 16, 2018	Results of AGM 2018	pdf	186 KB
November 16, 2018	AGM Presentation – Nov 2018	pdf	621 KB
October 16, 2018	Notice of AGM – Oct 2018	pdf	849 KB
July 16, 2018	Appendix 3B and 708A Notice – Jul 2018	pdf	248 KB
June 27, 2018	Investor Presentation – Jun 2018	pdf	5 MB
January 22, 2018	Appendix 3B – Jan 2018	pdf	809 KB

Financial reports

2022

October 28, 2022	Appendix 4C – Q1 FY 2023 Quarterly Cash Flow Report – 28 October 2022		662 KB
October 28, 2022	Appendix 4C – Q4 FY 2022 Quarterly Cash Flow Report – 22 July 2022		649 KB
September 1, 2022	Form 20-F 2022		850 KB
September 1, 2022	ATH Annual Report 2022		2 MB
April 29, 2022	Appendix 4C – Q3 FY 2022 Quarterly Cash Flow Report – 29 April 2022	pdf	1 MB
January 27, 2022	Appendix 4C – Q2 FY22 Quarterly Cash Flow Report – 27 January 2022		422 KB

2021

June 24, 2022	Half Year Financial Report Period to 31 Dec 2021	pdf	388 KB
October 29, 2021	Appendix 4C – September 2021	pdf	2 MB
September 3, 2021	Form 20-F 2021	pdf	776 KB
September 1, 2021	Annual Report 2021	pdf	3 MB
July 30, 2021	Appendix 4C-June 2021	pdf	411 KB
April 29, 2021	Appendix 4C – March 2021	pdf	418 KB
February 25, 2021	Appendix 4D 2020	pdf	374 KB

2020

January 29, 2021	Appendix 4C- December 2020	pdf	339 KB
October 30, 2020	Appendix 4C- September 2020	pdf	354 KB
September 16, 2020	Form 20-F 2020	pdf	2 MB
September 9, 2020	Appendix 4G Ended 30 June 2020	pdf	374 KB
September 9, 2020	Annual Report 2020	pdf	2 MB
August 31, 2020	Appendix 4E Year ended 30 June 2020	pdf	454 KB
July 30, 2020	Appendix 4C – June 2020	pdf	384 KB
April 30, 2020	Appendix 4C – March 2020	pdf	346 KB
February 28, 2020	Form 6-K Feb 2020	pdf	233 KB
February 28, 2020	Appendix 4D 2019	pdf	410 KB
January 31, 2020	Appendix 4C – December 2019	pdf	372 KB

2019

October 30, 2019	Appendix 4C – September 2019	pdf	346 KB
September 2, 2019	Form 20-F 2019	pdf	828 KB
August 30, 2019	Appendix 4G FY Ended 2019_06_30	pdf	341 KB
August 30, 2019	Annual Report 2019	pdf	1 MB
August 1, 2019	Appendix 4C – June 2019	pdf	151 KB
May 13, 2019	Form-6-K-2019_03_01	pdf	400 KB
April 16, 2019	Appendix 4C – Mar 2019	pdf	161 KB
February 28, 2019	Form 6-K – Mar 2019	pdf	400 KB
February 28, 2019	Appendix 4D 2018	pdf	217 KB
January 31, 2019	Appendix 4C – Dec 2018	pdf	234 KB

2018

May 13, 2019	Form 6-K Feb 2018	pdf	148 KB
October 30, 2018	Appendix 4C – Sept 2018	pdf	170 KB
September 3, 2018	Form 20F – 2018	pdf	2 MB
August 31, 2018	Appendix 4G FY Ended 2018_06_30	pdf	123 KB
August 31, 2018	Annual Report 2018	pdf	2 MB
July 30, 2018	Appendix 4C – Jun 2018	pdf	262 KB
May 7, 2018	Appendix 4C – Mar 2018	pdf	263 KB
March 4, 2018	Form 6-K Feb 2018	pdf	148 KB

Corporate governance

November 16, 2022	Alterity Therapeutics Constitution (Amended November 2022)		445 KB
September 13, 2022	Communication and Disclosure Policy		130 KB
September 13, 2022	Anti-Bribery and Anti-Corruption Policy		150 KB
September 13, 2022	Securities Trading Policy		182 KB
September 1, 2022	Corporate Governance Statement 2022		216 KB
April 29, 2020	Board Charter	pdf	1 MB
May 15, 2019	Whistle Blower Policy	pdf	320 KB
May 15, 2019	Diversity Policy	pdf	197 KB
November 23, 2020	2018 ADS Plan (as amended)	pdf	100 KB
November 23, 2020	2004 ASX Plan (as amended)	pdf	52 KB